Patient case (clinical description): A 50-year-old woman comes to the clinic with intermittent ear discharge and sense of hearing loss on her left ear.  Past medical history is significant for obesity, hyperlipidemia, and diabetes mellitus.  Her medications include Metformin, Atorvastatin and Vit D supplement. Vital signs are normal. BMI is 37. Otoscopy shows a small perforation in the left tympanic membrane and a pearly mass behind the membrane.  Conduction hearing loss is noted in the left ear.  The remainder of the ear, nose, and throat examination is normal.

Patient's own account: I went to the clinic the other day because I had some fluid in my ear and I felt like I could not hear as well as I used to in my left ear. I'm a 50-year-old woman, and I have been obese for a while now. I have diabetes and cholesterol. I take some medication. I take metformin, atorvastatin, and vitamin D supplements. When I was admitted, my vitals were normal. My BMI is 37. When they looked into my ears, they said that my left tympanic membrane was broken and there was some fluid behind the membrane. During the hearing test, they could assess that my left ear suffers from hearing loss. They also performed ear, nose, and throat examinations that turned out to be normal.

Clinical trial: A Real World Research: Comparison of Precision and Experience Therapy for Hypertension, Diabetes or Hyperlipidemias

Eligibility criteria:
Inclusion Criteria:

          1. They are 55 years old or above, with no gender restriction. They are permanent
             residents of Da-jie town and Jiu-zhi Township in Da-ming County.

          2. Patients who meet one of the following:

             A. Hypertension project group:

             Primary hypertension was definitely diagnosed, systolic blood pressure ≥ 140
             millimeter of mercury, diastolic blood pressure ≥ 90 millimeter of mercury, or both
             after drug treatment.

             B.Type 2 Diabetes project group:

             Patients with type 2 diabetes mellitus (non insulin dependent diabetes mellitus) who
             were diagnosed as type 2 diabetes mellitus (NIDDM) and had HbA1c ≥ 7.0% after drug
             treatment before enrollment.

             C.Hyperlipidemia project group:

             Those who were diagnosed as hyperlipidemia and were treated with or without medication
             before enrollment.

          3. Patients who can provide real and reliable information related to drug treatment and
             efficacy evaluation

        Exclusion Criteria:

          1. Respondents who are not willing to fill in the true and reliable information form for
             any reason.

          2. Patients with infectious diseases or serious life-threatening diseases such as
             malignant tumors.

          3. Patients with severe liver and kidney function damage, affecting the choice of
             treatment drugs.

          4. Patients with incomplete data related to study evaluation such as any of following:

        A.The clinical data did not include systolic blood pressure, diastolic blood pressure,
        heart rate, glycosylated hemoglobin, fasting blood glucose, total cholesterol, low-density
        lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride core efficacy
        evaluation indicators.

        B.The data related to adverse reactions required by clinical research can not be collected,
        including but not limited to the related drugs with adverse reactions, adverse reaction
        performance, time correlation, whether to stop suspicious drugs, and whether to stimulate
        adverse reactions by re-medication.

        C.The information of medication compliance score and quality of life score could not be
        provided for any reason.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 55 Years old.
Subject must be at most 120 Years

Eligibility (NLI label): Contradiction